Abstract
Leishmaniasis is listed by the World Health Organization as a neglected tropical disease. The medicines used to treat leishmaniasis are relatively expensive and therefore often unaffordable toxic. These drugs besides being toxic, confer resistance, few or no antileishmanial drugs are under development or have been approved for use recently. This review provides an overview of various synthetic compounds containing the sulfonamide group linked to heterocyclic rings that have been evaluated against Leishmania spp. and could be considered possible prototypes to develop new drugs to treat this disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
